Volume 6 Supplement 2
Treatment of advanced thyroid cancer refractory to therapy
- Barbara Jarząb1
© Jarzab; licensee BioMed Central Ltd. 2013
Published: 5 April 2013
Radioiodine treatment constitutes the most effective therapeutic option of advanced differentiated thyroid cancer. Unfortunately, about 30% cancers do not show radioiodine uptake or do not respond to therapy.
Mechanism of action
Clinical trials (phase)
VEGFR1,2,3, PDGFR, c-KIT, RET
B-RAF, VEGFR1, VEGFR2
VEGFR, c-KIT, PDGFR-B
VEGFR1, 2, PDGFR, c-KIT, FLT3, RET
VEGFR1,2,3, FGFR1 PDGFR
MET, VEGFR2, RET
VEGFR, PDGFR, c-KIT
RET, VEGFR, VEGFR2, EGFR
Until now the only registered drug in advanced MTC is vandetanib. Its efficacy has been proved in phase III study. Significant prolongation of progression free survival (PFS) was observed for patients receiving vandetanib compared with placebo group (30.5 months vs. 19 months, respectively). Published results of phase II studies have preliminarily proved the efficacy of axitinib, sorafenib and sunitinib in DTC (beneficial therapeutic effects of partial regression or disease stabilization was noticed in 68%, 76% and 75% cases, respectively). The highest response rate (partial regression) was obtained in DTC patients treated with pazopanib (49%). Whereas, in phase II clinical trials with cabozantynib, motesanib and sorafenib carried out in MTC, disease control was achieved in 90%, 83% and 94% patients, respectively.
The most common side effects are skin reactions such as photosensitivity, rash, hand-food syndrome, arterial hypertension, gastrointestinal – diarrhea, nausea, vomiting, stomatitis and decrease in body weight. Majority of them have slight or moderate intensiveness (G1 and G2 according to Common Terminology Criteria for Adverse Events). The tolerability of TKI is acceptable and does not affect the quality of life.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.